Haolan Yu

Haolan Yu

Auto-generated profile, based on publicly available information

Haolan Yu

Hangzhou Medical College 1 Otolaryngology & Head and Neck Center, Cancer Center, Department of Head and Neck Surgery, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital) Hangzhou, China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
LJLiehao Jiang
Liehao Jiang
XLXuejie Li
Xuejie Li
TMTianyi Ma
Tianyi Ma
PZPingping Zeng
Pingping Zeng
ZTZhuo Tan
Zhuo Tan
MGMinghua Ge
Minghua Ge
Purpose: Preoperative risk stratification for papillary thyroid cancer (PTC) is a significant clinical challenge as current systems primarily rely on postoperative pathology, limiting their utility for initial treatment planning. This study aimed to evaluate the effectiveness of using circulating tumor cells (CTC) as a noninvasive liquid biopsy tool to stratify patient risk preoperatively. Experimental Design: We conducted a prospective study evaluating preoperative CTC levels in 210 patients diagnosed with PTC. A dual-threshold model was developed to analyze the diagnostic performance of CTC counts. The study particularly focused on the papillary thyroid microcarcinoma (PTMC) subgroup (n = 100) to address clinical uncertainty with regard to active surveillance versus definitive therapy. Patients were monitored over a median follow-up period of 44 months to assess progression-free survival (PFS) and long-term prognostic outcomes. Results: The dual-threshold model demonstrated excellent diagnostic performance. A cutoff of ≥2 CTCs effectively identified high-risk patients with 93.2% specificity and 88.2% positive predictive value (PPV). In the PTMC cohort, a CTC count <2 reliably identified low-risk patients suitable for active surveillance (negative predictive value = 94%), whereas a count ≥2 pinpointed those with high-risk features warranting surgery (specificity = 96.4% and PPV = 80%). Prognostic analysis revealed that CTC-negative patients had improved PFS. This was most significant in the PTMC subgroup, in which the CTC-negative cohort remained recurrence free and showed significantly longer PFS compared with CTC-positive cases (HR = 0.035; 95% confidence interval, 0.002–0.726; P = 0.030). Conclusions: Preoperative CTC detection enables precise risk stratification for patients with PTC. This liquid biopsy approach allows clinicians to personalize therapy—confidently selecting conservative management for low-risk individuals and recommending aggressive treatment for high-risk patients—thereby optimizing clinical decision-making and long-term outcomes.

1 April 2026
Verified
Other
Open access
LJLiehao Jiang
Liehao Jiang
XLXuejie Li
Xuejie Li
TMTianyi Ma
Tianyi Ma
PZPingping Zeng
Pingping Zeng
ZTZhuo Tan
Zhuo Tan
MGMinghua Ge
Minghua Ge
<p>Table S1、S2; Figure S1、Figure S2、Figure S3</p>

3 November 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HYHaolan Yu
Haolan Yu
LJLiehao Jiang
Liehao Jiang
ZTZhuo Tan
Zhuo Tan
JWJie Wu
Jie Wu
MGMinghua Ge
Minghua Ge
Head and neck squamous cell carcinoma (HNSCC) represents a significant public health challenge. Its treatment is characterized by high anatomical complexity and a critical need for functional preservation of speech, swallowing, and respiration. While multimodality care, including surgery, radiotherapy, and systemic therapy, has substantially improved patient survival, there are still high rates of life-altering toxicities and low response rates to immunotherapy. Current clinical decision-making largely relies on “digital snapshots”—static representations derived from population-based statistics and time point–specific imaging—which usually fail to account for the rapid anatomical and biological change during the course of treatment. Digital twins hold great promise in accelerating scientific breakthroughs and transforming oncology treatment and precision medicine through the creation of high-fidelity virtual patient representations that integrate real-time biological, anatomical, and clinical data. In this viewpoint, we propose 3 interconnected digital twins to establish a conceptual framework for the HNSCC digital twin. These digital twins include the anatomical twin, using virtual surgical planning and augmented reality for geometric precision; the dosimetric twin, using daily imaging and synthetic computed tomography generation for automated adaptive radiotherapy; and the biological twin, integrating deep phenotyping, radiomics, and mechanistic omics to simulate individualized therapeutic trajectories. Beyond acute care, we explore the clinical utility of digital twins in navigating the “de-escalation dilemma” for human papillomavirus–associated disease and improving survivorship through digital phenotyping. With the advent of longitudinal data from medical-grade Internet-of-Things sensors and circulating tumor DNA kinetics, digital twins can serve as active sentinels, detecting functional decline or subclinical events months before clinical manifestation. Furthermore, the implementation of synthetic control arms via virtual populations offers an avenue to accelerate clinical trials and address ethical issues in rare molecular subtypes. Despite this potential, substantial barriers to implementation remain, including profound anatomical instability during treatment, the “black box” nature of deep learning algorithms, and the challenges of multiscale data integration. We provide a technical roadmap for the development of “morphing” digital twins—dynamic systems capable of continuous geometric and biological auditing. By bridging the gap between the macroscopic world of radiation physics and the microscopic world of cellular evolution, digital twins may help shift the management of HNSCC from population-based statistical probability toward more individualized, biologically informed decision-making, with the goal of optimizing HNSCC management while preserving essential patient functions.

1 April 2026
Verified
Other
Open access
LJLiehao Jiang
Liehao Jiang
XLXuejie Li
Xuejie Li
TMTianyi Ma
Tianyi Ma
PZPingping Zeng
Pingping Zeng
ZTZhuo Tan
Zhuo Tan
MGMinghua Ge
Minghua Ge
Purpose:Preoperative risk stratification for papillary thyroid cancer (PTC) is a significant clinical challenge as current systems primarily rely on postoperative pathology, limiting their utility for initial treatment planning. This study aimed to evaluate the effectiveness of using circulating tumor cells (CTC) as a noninvasive liquid biopsy tool to stratify patient risk preoperatively.Experimental Design:We conducted a prospective study evaluating preoperative CTC levels in 210 patients diagnosed with PTC. A dual-threshold model was developed to analyze the diagnostic performance of CTC counts. The study particularly focused on the papillary thyroid microcarcinoma (PTMC) subgroup (n = 100) to address clinical uncertainty with regard to active surveillance versus definitive therapy. Patients were monitored over a median follow-up period of 44 months to assess progression-free survival (PFS) and long-term prognostic outcomes.Results:The dual-threshold model demonstrated excellent diagnostic performance. A cutoff of ≥2 CTCs effectively identified high-risk patients with 93.2% specificity and 88.2% positive predictive value (PPV). In the PTMC cohort, a CTC count <2 reliably identified low-risk patients suitable for active surveillance (negative predictive value = 94%), whereas a count ≥2 pinpointed those with high-risk features warranting surgery (specificity = 96.4% and PPV = 80%). Prognostic analysis revealed that CTC-negative patients had improved PFS. This was most significant in the PTMC subgroup, in which the CTC-negative cohort remained recurrence free and showed significantly longer PFS compared with CTC-positive cases (HR = 0.035; 95% confidence interval, 0.002–0.726; P = 0.030).Conclusions:Preoperative CTC detection enables precise risk stratification for patients with PTC. This liquid biopsy approach allows clinicians to personalize therapy—confidently selecting conservative management for low-risk individuals and recommending aggressive treatment for high-risk patients—thereby optimizing clinical decision-making and long-term outcomes.